Daehan Pharmaceutical대한약품
023910 · KOSDAQ · ₩023910 · 대한약품
₩25,000▲ ₩100 (0.40%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩209B | ₩204B | ₩196B | ₩184B | ₩171B |
| Cost of sales | ₩144B | ₩134B | ₩130B | ₩124B | ₩115B |
| Gross profit | ₩65B | ₩70B | ₩66B | ₩60B | ₩56B |
| Operating income | ₩31B | ₩38B | ₩36B | ₩33B | ₩29B |
| Net income | ₩28B | ₩34B | ₩28B | ₩25B | ₩23B |
| Net income to shareholders | ₩28B | ₩34B | ₩28B | ₩25B | ₩23B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩348B | ₩324B | ₩294B | ₩277B | ₩273B |
| Current assets | ₩158B | ₩137B | ₩160B | ₩156B | ₩148B |
| Cash and equivalents | ₩44B | ₩61B | ₩102B | ₩91B | ₩84B |
| Total liabilities | ₩47B | ₩48B | ₩46B | ₩52B | ₩70B |
| Current liabilities | ₩44B | ₩43B | ₩41B | ₩43B | ₩46B |
| Borrowings | — | — | ₩0 | ₩6.5B | ₩24B |
| Total equity | ₩300B | ₩276B | ₩248B | ₩225B | ₩203B |
| Shareholders' equity | ₩300B | ₩276B | ₩248B | ₩225B | ₩203B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩26B | ₩36B | ₩39B | ₩29B | ₩41B |
| Capital spending | ₩25B | ₩16B | — | ₩8.6B | ₩12B |
| Free cash flow | ₩482M | ₩20B | ₩39B | ₩20B | ₩29B |
| Dividends paid | ₩5.2B | ₩4.3B | ₩0 | ₩2.1B | ₩2.1B |
Consolidated where available. Amounts in won.
Also known as: Daehan Pharmaceutical / 대한약품 / 023910 / KRX:023910
Source: KRX statistical information